These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 15765031

  • 1. New therapeutic options for acromegaly.
    Arosio M, Ronchi CL, Epaminonda P, di Lembo S, Adda G.
    Minerva Endocrinol; 2004 Dec; 29(4):225-39. PubMed ID: 15765031
    [Abstract] [Full Text] [Related]

  • 2. Acromegaly.
    Scacchi M, Cavagnini F.
    Pituitary; 2006 Dec; 9(4):297-303. PubMed ID: 17077948
    [Abstract] [Full Text] [Related]

  • 3. [Acromegaly--do we already know everything about treatment of the somatotroph pituitary adenomas?].
    Zieliński G, Podgórski JK.
    Przegl Lek; 2002 Dec; 59(7):540-7. PubMed ID: 12516247
    [Abstract] [Full Text] [Related]

  • 4. Therapy for the syndromes of GH excess.
    Arosio M, Cannavò S, Epaminonda P, Ronchi C, Chiodini I, Adda G.
    J Endocrinol Invest; 2003 Dec; 26(10 Suppl):36-43. PubMed ID: 15497658
    [Abstract] [Full Text] [Related]

  • 5. [Outcome of somatostatin analogue treatment in acromegaly].
    Mondok A, Tóth M, Patócs A, Szücs N, Igaz P, Pusztai P, Czirják S, Beko G, Gláz E, Rácz K, Tulassay Z.
    Orv Hetil; 2009 Aug 02; 150(31):1457-62. PubMed ID: 19617182
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Advances in the treatment of acromegaly].
    Krysiak R, Okopień B, Marek B.
    Pol Merkur Lekarski; 2008 Jan 02; 24(139):59-65. PubMed ID: 18634256
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A.
    Neuroendocrinology; 2006 Jan 02; 83(3-4):249-57. PubMed ID: 17047390
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Novel pharmacologic therapies in acromegaly].
    Góth M, Hubina E, Kovács L, Szabolcs I.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [Abstract] [Full Text] [Related]

  • 15. Acromegaly.
    Dineen R, Stewart PM, Sherlock M.
    QJM; 2017 Jul 01; 110(7):411-420. PubMed ID: 26873451
    [Abstract] [Full Text] [Related]

  • 16. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
    van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW.
    J Clin Endocrinol Metab; 2001 Feb 01; 86(2):478-81. PubMed ID: 11157994
    [Abstract] [Full Text] [Related]

  • 17. Acromegaly: a review of current medical therapy and new drugs on the horizon.
    Fleseriu M, Delashaw JB, Cook DM.
    Neurosurg Focus; 2010 Oct 01; 29(4):E15. PubMed ID: 20887125
    [Abstract] [Full Text] [Related]

  • 18. Octreotide as primary therapy for acromegaly.
    Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL.
    J Clin Endocrinol Metab; 1998 Sep 01; 83(9):3034-40. PubMed ID: 9745397
    [Abstract] [Full Text] [Related]

  • 19. [Therapeutic management of acromegaly].
    Metzner C, Hadziselimovic S, Grafe I, Nawroth P, Kasperk C.
    Med Klin (Munich); 2006 Jan 15; 101(1):15-23. PubMed ID: 16418810
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.